METTL3 and central nervous system cancer: The TMA data revealed that METTL3 protein levels were significantly elevated in high-grade gliomas (WHO grades III and IV) compared to low-grade gliomas (WHO grade II) and non-tumor brain tissue (Figures 1A and 1B).